[A25-95 ] Efgartigimod alfa (Chronic inflammatory demyelinating polyneuropathy) – Benefit assessment according to § 35a SGB V
Last updated 03.11.2025
Project no.:
A25-95
Commission:
Commission awarded on 24.07.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Adults with progressive or recurrent active chronic inflammatory demyelinating polyneuropathy after previous treatment with corticosteroids or immunoglobulins
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-95
| Project no. | Title | Status |
|---|---|---|
| A24-36 | Efgartigimod alfa (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G22-29 | Efgartigimod alfa (myasthenia gravis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |